Recombinant Interferon Alfa 2a

Phase 3Small molecule

Recombinant Interferon Alfa 2a is one of 127 small molecule programs targeting Von Willebrand disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

StrokeActive, not recruiting

Intracranial HemorrhageActive, not recruiting

Hemophilia aActive, not recruiting

GrowthActive, not recruiting

Von Willebrand DiseasePreclinical

Active, not recruiting

StrokePhase 3

Active, not recruiting

Intracranial HemorrhagePhase 1

Active, not recruiting

Hemophilia aPhase 2

Active, not recruiting

GrowthPhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Recombinant Interferon Alfa 2a

Roche

Phase 3

1 2

Activase

Roche

Preclinical

19 3

Zometa

Pfizer

Preclinical

1 4

Savella

AbbVie

Preclinical

1 5

Proamatine

Repatha

Pradaxa

3 8

Inderal

Mylan Pharmaceuticals Inc

Antidepressant

1 10

Atorvastatin Calcium

Merck & Co.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Active, not recruiting

Von Willebrand Disease, Type 3

NCT06883240

Q1 2028

Phase 3Active, not recruiting

Stroke

NCT03496883

Clinical

Trials by Indication[1]

Treatment1 trial

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Completed· Roche logo

Roche·Phase 2/3·NCT02829775·9 enrolled

Intracranial Hemorrhage1 trial

Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage

Terminated·UUniversity of Utah·Phase 1·NCT00770718·2 enrolled

Stroke1 trial

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Active, not recruiting·—·Phase 3·NCT03496883·860 enrolled

Cardiopulmonary Bypass1 trial

Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass

Completed·EEmory University··NCT01352143·24 enrolled

Cardiac Surgery1 trial

"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery

Unknown status·AAustin Health·Phase 3·NCT00214656·40 enrolled

3 more indications

Growth1 trial

The Spot Sign for Predicting and Treating ICH Growth Study

Completed·UUniversity of Cincinnati·Phase 2·NCT00810888·92 enrolled

Hemophilia A1 trial

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 2·NCT01105546·50 enrolled

Von Willebrand Disease, Type 31 trial

A Multicenter Non-Interventional Study Evaluating Bleeds and Health-Related Quality Of Life in Patients With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

Active, not recruiting· Roche logo

Roche··NCT06883240·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Recombinant Interferon Alfa 2a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Interferon Alfa 2a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Interferon Alfa 2a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Recombinant Interferon Alfa 2a

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

Treatment1 trial

Intracranial Hemorrhage1 trial

Stroke1 trial

Cardiopulmonary Bypass1 trial

Cardiac Surgery1 trial

Growth1 trial

Hemophilia A1 trial

Von Willebrand Disease, Type 31 trial

References

Drug Info

Quick Facts

Related News